Y-mAbs Therapeutics (NASDAQ:YMAB) posted its earnings results on Wednesday. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.05), Fidelity Earnings reports.
Shares of YMAB traded up $0.37 on Thursday, reaching $26.53. The company’s stock had a trading volume of 1,597 shares, compared to its average volume of 119,870. The company has a quick ratio of 13.30, a current ratio of 13.30 and a debt-to-equity ratio of 0.02. Y-mAbs Therapeutics has a twelve month low of $15.17 and a twelve month high of $31.00. The firm has a market cap of $810.39 million and a PE ratio of -17.95. The company has a fifty day moving average of $22.95.
In related news, insider Thomas Gad sold 4,000 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $21.78, for a total value of $87,120.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders sold a total of 30,000 shares of company stock worth $646,500 in the last 90 days. 38.40% of the stock is currently owned by company insiders.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
See Also: What is meant by a buy rating?
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.